Literature DB >> 29581131

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.

Anosheh Afghahi1, Natasha Purington2, Summer S Han2, Manisha Desai2,3, Emma Pierson4, Maya B Mathur2,5, Tina Seto4, Caroline A Thompson6,7, Joseph Rigdon2, Melinda L Telli4, Sunil S Badve8, Christina N Curtis4, Robert B West9, Kathleen Horst4, Scarlett L Gomez4,10, James M Ford4, George W Sledge4, Allison W Kurian11,4.   

Abstract

Purpose: Tumor-infiltrating lymphocytes (TIL) in pretreatment biopsies are associated with improved survival in triple-negative breast cancer (TNBC). We investigated whether higher peripheral lymphocyte counts are associated with lower breast cancer-specific mortality (BCM) and overall mortality (OM) in TNBC.Experimental Design: Data on treatments and diagnostic tests from electronic medical records of two health care systems were linked with demographic, clinical, pathologic, and mortality data from the California Cancer Registry. Multivariable regression models adjusted for age, race/ethnicity, socioeconomic status, cancer stage, grade, neoadjuvant/adjuvant chemotherapy use, radiotherapy use, and germline BRCA1/2 mutations were used to evaluate associations between absolute lymphocyte count (ALC), BCM, and OM. For a subgroup with TIL data available, we explored the relationship between TILs and peripheral lymphocyte counts.
Results: A total of 1,463 stage I-III TNBC patients were diagnosed from 2000 to 2014; 1,113 (76%) received neoadjuvant/adjuvant chemotherapy within 1 year of diagnosis. Of 759 patients with available ALC data, 481 (63.4%) were ever lymphopenic (minimum ALC <1.0 K/μL). On multivariable analysis, higher minimum ALC, but not absolute neutrophil count, predicted lower OM [HR = 0.23; 95% confidence interval (CI), 0.16-0.35] and BCM (HR = 0.19; CI, 0.11-0.34). Five-year probability of BCM was 15% for patients who were ever lymphopenic versus 4% for those who were not. An exploratory analysis (n = 70) showed a significant association between TILs and higher peripheral lymphocyte counts during neoadjuvant chemotherapy.Conclusions: Higher peripheral lymphocyte counts predicted lower mortality from early-stage, potentially curable TNBC, suggesting that immune function may enhance the effectiveness of early TNBC treatment. Clin Cancer Res; 24(12); 2851-8. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29581131      PMCID： PMC6366842          DOI： 10.1158/1078-0432.CCR-17-1323

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  40 in total

1.  STRIDE--An integrated standards-based translational research informatics platform.

Authors:  Henry J Lowe; Todd A Ferris; Penni M Hernandez; Susan C Weber
Journal:  AMIA Annu Symp Proc       Date:  2009-11-14

Review 2.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

3.  Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research.

Authors:  Susan C Weber; Tina Seto; Cliff Olson; Pragati Kenkare; Allison W Kurian; Amar K Das
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

4.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

5.  Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors.

Authors:  Adrienne G Waks; Sara M Tolaney; Alicia Galar; Amal Arnaout; Julie B Porter; Francisco M Marty; Eric P Winer; Sarah P Hammond; Lindsey R Baden
Journal:  Breast Cancer Res Treat       Date:  2015-09-29       Impact factor: 4.872

6.  Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.

Authors:  Udaya K Liyanage; Todd T Moore; Hong-Gu Joo; Yoshiyuki Tanaka; Virginia Herrmann; Gerard Doherty; Jeffrey A Drebin; Steven M Strasberg; Timothy J Eberlein; Peter S Goedegebuure; David C Linehan
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

7.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

Authors:  Gaynor J Bates; Stephen B Fox; Cheng Han; Russell D Leek; José F Garcia; Adrian L Harris; Alison H Banham
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

8.  Lymphocytopenia as an independent predictor of early recurrence in breast cancer.

Authors:  C W Pattison; K L Woods; J M Morrison
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

9.  The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.

Authors:  S R Young; Robert T Pilarski; Talia Donenberg; Charles Shapiro; Lyn S Hammond; Judith Miller; Karen A Brooks; Stephanie Cohen; Beverly Tenenholz; Damini Desai; Inuk Zandvakili; Robert Royer; Song Li; Steven A Narod
Journal:  BMC Cancer       Date:  2009-03-19       Impact factor: 4.430

10.  Breast cancer treatment across health care systems: linking electronic medical records and state registry data to enable outcomes research.

Authors:  Allison W Kurian; Aya Mitani; Manisha Desai; Peter P Yu; Tina Seto; Susan C Weber; Cliff Olson; Pragati Kenkare; Scarlett L Gomez; Monique A de Bruin; Kathleen Horst; Jeffrey Belkora; Suepattra G May; Dominick L Frosch; Douglas W Blayney; Harold S Luft; Amar K Das
Journal:  Cancer       Date:  2013-09-24       Impact factor: 6.921
View more
  35 in total

1.  Acute kidney injury as an independent predictor of infection and malignancy: the NARA-AKI cohort study.

Authors:  Miho Tagawa; Masatoshi Nishimoto; Maiko Kokubu; Masaru Matsui; Masahiro Eriguchi; Ken-Ichi Samejima; Yasuhiro Akai; Kazuhiko Tsuruya
Journal:  J Nephrol       Date:  2019-10-15       Impact factor: 3.902

2.  Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy.

Authors:  Shiwei Liu; Shiyan Zeng; Li Xia; Miao Yu; Xin Zhang; Hong Yang; Juan Ji; Hao Dong; Jianhui Zhang; Purong Zhang
Journal:  Breast Cancer Res Treat       Date:  2020-11-09       Impact factor: 4.872

3.  Systemic Inflammation After Radiation Predicts Locoregional Recurrence, Progression, and Mortality in Stage II-III Triple-Negative Breast Cancer.

Authors:  Alexander D Sherry; Rie von Eyben; Neil B Newman; Paulina Gutkin; Ingrid Mayer; Kathleen Horst; A Bapsi Chakravarthy; Marjan Rafat
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-12-03       Impact factor: 7.038

4.  A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.

Authors:  J Watanabe; M Saito; Y Horimoto; S Nakamoto
Journal:  Breast Cancer Res Treat       Date:  2020-04-05       Impact factor: 4.872

Review 5.  Organoids as Complex In Vitro Models for Studying Radiation-Induced Cell Recruitment.

Authors:  Benjamin C Hacker; Marjan Rafat
Journal:  Cell Mol Bioeng       Date:  2020-06-15       Impact factor: 2.321

6.  Novel lymphocyte to red blood cell ratio (LRR), neutrophil to red blood cell ratio (NRR), monocyte to red blood cell ratio (MRR) as predictive and prognostic biomarkers for locally advanced breast cancer.

Authors:  Yaohui Wang; Haofeng Wang; Wenjin Yin; Yanping Lin; Liheng Zhou; Xiaonan Sheng; Yaqian Xu; Rui Sha; Jinsong Lu
Journal:  Gland Surg       Date:  2019-12

7.  Lymphopenia association with accelerated hyperfractionation and its effects on limited-stage small cell lung cancer patients' clinical outcomes.

Authors:  Xin Wang; Jie Lu; Feifei Teng; Jinming Yu
Journal:  Ann Transl Med       Date:  2019-08

8.  The population characteristics of the main leukocyte subsets and their association with chronic diseases in a community-dwelling population: a cross-sectional study.

Authors:  Wangyang Chen; Jixi Wang; Bintao Ye; Jun Zhou; Weibo Wang
Journal:  Prim Health Care Res Dev       Date:  2021-05-07       Impact factor: 1.458

9.  Relationship of circulating immune cells with lifestyle factors and cancer recurrence in early-stage breast cancer.

Authors:  Eric Xie; Maya M Lapinski; Sarah Talamantes; Bareng A S Nonyane; Maria Cristina Figueroa Magalhães; Kala Visvanathan; Antonio C Wolff; Cesar A Santa-Maria
Journal:  Breast Cancer Res Treat       Date:  2020-11-13       Impact factor: 4.624

Review 10.  Triple-negative breast cancer: new treatment strategies in the era of precision medicine.

Authors:  Song-Yang Wu; Hai Wang; Zhi-Ming Shao; Yi-Zhou Jiang
Journal:  Sci China Life Sci       Date:  2020-08-11       Impact factor: 6.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.